Fiduciary Group LLC Has $6 Million Stock Position in Becton, Dickinson and Company (NYSE:BDX)

Fiduciary Group LLC decreased its position in Becton, Dickinson and Company (NYSE:BDX) by 1.7% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 25,690 shares of the medical instruments supplier’s stock after selling 456 shares during the quarter. Fiduciary Group LLC’s holdings in Becton, Dickinson and Company were worth $6,004,000 as of its most recent SEC filing.

A number of other large investors also recently made changes to their positions in BDX. Norges Bank acquired a new position in shares of Becton, Dickinson and Company during the 4th quarter worth approximately $761,798,000. Nordea Investment Management AB grew its position in Becton, Dickinson and Company by 277.3% during the first quarter. Nordea Investment Management AB now owns 1,936,654 shares of the medical instruments supplier’s stock worth $478,295,000 after buying an additional 1,423,353 shares in the last quarter. PineStone Asset Management Inc. increased its stake in Becton, Dickinson and Company by 141.6% during the 2nd quarter. PineStone Asset Management Inc. now owns 1,345,873 shares of the medical instruments supplier’s stock worth $314,544,000 after acquiring an additional 788,735 shares during the period. M&G Plc bought a new stake in shares of Becton, Dickinson and Company during the 1st quarter valued at $173,692,000. Finally, Bank of New York Mellon Corp grew its holdings in shares of Becton, Dickinson and Company by 8.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 4,412,163 shares of the medical instruments supplier’s stock worth $1,031,167,000 after purchasing an additional 346,720 shares in the last quarter. Institutional investors own 86.97% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently weighed in on BDX shares. Citigroup cut their price objective on shares of Becton, Dickinson and Company from $260.00 to $255.00 and set a “neutral” rating for the company in a research report on Wednesday, July 10th. The Goldman Sachs Group began coverage on shares of Becton, Dickinson and Company in a research report on Thursday, May 30th. They set a “buy” rating and a $274.00 price target on the stock. Stifel Nicolaus upped their target price on Becton, Dickinson and Company from $270.00 to $280.00 and gave the stock a “buy” rating in a research note on Friday, July 26th. StockNews.com raised Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Thursday, August 8th. Finally, Evercore ISI lowered their price target on Becton, Dickinson and Company from $290.00 to $285.00 and set an “outperform” rating for the company in a report on Tuesday, July 2nd. One investment analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $279.50.

Becton, Dickinson and Company Price Performance

Becton, Dickinson and Company stock opened at $233.94 on Friday. The company has a market capitalization of $67.62 billion, a PE ratio of 51.53, a P/E/G ratio of 1.91 and a beta of 0.42. The company has a current ratio of 1.85, a quick ratio of 1.36 and a debt-to-equity ratio of 0.70. The stock has a 50-day moving average price of $234.71 and a two-hundred day moving average price of $235.67. Becton, Dickinson and Company has a 12 month low of $218.75 and a 12 month high of $269.52.

Becton, Dickinson and Company (NYSE:BDX) last posted its earnings results on Thursday, August 1st. The medical instruments supplier reported $3.50 EPS for the quarter, topping the consensus estimate of $3.31 by $0.19. Becton, Dickinson and Company had a net margin of 7.13% and a return on equity of 14.49%. The business had revenue of $4.99 billion for the quarter, compared to the consensus estimate of $5.08 billion. During the same period last year, the company earned $2.96 EPS. The firm’s revenue was up 2.3% compared to the same quarter last year. Analysts expect that Becton, Dickinson and Company will post 13.1 EPS for the current year.

Becton, Dickinson and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, September 30th. Investors of record on Monday, September 9th will be issued a $0.95 dividend. The ex-dividend date is Monday, September 9th. This represents a $3.80 dividend on an annualized basis and a yield of 1.62%. Becton, Dickinson and Company’s payout ratio is 83.70%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.